Home » Healthcare » Pharmaceuticals » Neurotrophic Keratitis Market

Neurotrophic Keratitis Market By Treatment (Preservative Free Artificial Tears, Topical Antibiotics, Tarsorraphy, Amniotic Membrane Transplantation, Bandage Contact Lenses, Recombinant Human Nerve Growth Factor) – Growth, Future Prospects And Competitive Landscape, 2019 – 2027

Summary
Table Of Content

Market Insights

The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027. Neurotrophic keratitis is an orphan disease that is primarily caused by the damage of the fifth cranial nerve from the trigeminal nucleus to the nerve endings present in the corneal region of the eye.

Traditional therapies are employed to suppress the clinical manifestations occurring at different stages of the disease. Currently, RGN-259, developed by ReGenTree, LLC, is in phase III clinical trial study for the treatment of neurotrophic keratitis.

Market Synopsis

Recent EMA approval of Oxervate and priority review designation approved by the USFDA will popularise the recombinant human nerve growth factor during the forecast period.

Neurotrophic keratitis is a rare degenerative disease that results in a loss of corneal sensation and dampens the healing process. The global prevalence rate of neurotrophic keratitis is reported to be 5 per 10,000 individuals. The treatment options adopted for neurotrophic keratitis depend on the severity and stage of the disease. Artificial tears are prescribed for all stages due to their ability to provide wetness and lubrication to the corneal surface and ensure cleanliness. Topical antibiotics are mostly prescribed during stage 2 of the disease for prophylactic treatment of infection.

Despite pharmacological treatment, in stage 3 of the disease, surgical interventions such as cartography and amniotic membrane transplantation are employed to heal corneal ulceration. The recent approval of Oxervate by the EMA and priority review designation approved by the USFDA will popularise the utilization of recombinant human nerve growth factor for the treatment of neurotrophic keratitis during the forecast period.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Rising prevalence of neurotrophic keratitis and an affordable reimbursement scenario drive market growth in North America.

North America is presently responsible for 33% of the market share and is leading the regional segment for neurotrophic keratitis. According to the American Academy of Ophthalmology (AAO), approximately 65,000 people in the United States are suffering from this rare disease.

The chief contributing factors to its dominance in the regional market are the rising prevalence of neurotrophic keratitis and the affordability of the reimbursement scenario pertaining to the medication used for its treatment.

Europe trails North America in the regional market with a share of 28.5%, primarily due to strategic collaboration between government healthcare agencies and academic research institutes for the development of novel drugs for treating neurotrophic keratitis in Europe.

The European Medicines Agency (EMA) has designated neurotrophic keratitis as an orphan disease and has granted it fast-track status for drug development and sale in the region. Asia Pacific holds a 16% market share owing to the increasing incidence rate of neurotrophic keratitis in the geriatric population and supportive regulatory scenarios provided by regional healthcare agencies.

Periods of History and Forecast

This research report presents the analysis of each segment from 2017 to 2027,considering2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Scope by Segments

The market is segmented by treatment and by geography.

Pharmaceutical companies specializing in providing medication for the treatment of neurotrophic keratitis are Allergan, Plc., Abbott Laboratories, Inc., Bausch & Lomb Incorporated, Bayer AG, CooperVision, Dompe Farmaceutici S.p.A., Johnson & Johnson, Novartis AG, ReGenTree, LLC., and Walgreens.

Key questions are answered in this report.

Which strategic collaborations, mergers, and acquisitions are taking place in the neurotrophic keratitis market?
Which key players are manufacturing medicines for the treatment of neurotrophic keratitis?
What is the disease etiology of neurotrophic keratitis, and what medicines are prescribed as per the different stages of the disease?
What is Oxervate, and how will it perform during the forecast period?
What will be the market performance of developing regions such as Asia Pacific and Latin America in the neurotrophic keratitis market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Treatment
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global NK Market Portraiture
2.2. Global NK Market, by Treatment, 2018 (US$ Mn)
2.3. Global NK Market, by Geography, 2018 (US$ Mn)

Chapter 3. Neurotrophic Keratitis (NK) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global NK Market, by Key Players, 2018

Chapter 4. Global Neurotrophic Keratitis (NK) Market, by Treatment
4.1. Overview
4.2. Preservative Free Artificial Tears
4.3. Topical Antibiotics
4.4. Tarsorraphy
4.5. Amniotic Membrane Transplantation
4.6. Bandage Contact Lenses
4.7. Recombinant Human Nerve Growth Factor (Oxervate)
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. RGN-259

Chapter 5. Global Neurotrophic Keratitis (NK) Market, by Geography
5.1. Overview
5.2. North America NK Market Analysis, 2017 – 2027
5.2.1. North America NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.2.2. North America NK Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe NK Market Analysis, 2017– 2027
5.3.1. Europe NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.3.2. Europe NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific NK Market Analysis, 2017 – 2027
5.4.1. Asia Pacific NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America NK Market Analysis, 2017 – 2027
5.5.1. Latin America NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.5.2. Latin America NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa NK Market Analysis, 2017 – 2027
5.6.1. MEA NK Market, by Treatment, 2017 – 2027 (US$ Mn)
5.6.2. MEA NK Market, by Region, 2017– 2027 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Abbott Laboratories, Inc.
6.3. Bausch & Lomb Incorporated
6.4. Bayer AG
6.5. CooperVision
6.6. Dompe farmaceutici S.p.A.
6.7. Johnson & Johnson
6.8. Novartis AG
6.9. ReGenTree, LLC.
6.10. Walgreens

List of Figures

FIG. 1 : Neurotrophic Keratitis (NK) Market: Research Methodology
FIG. 2 : NK: Market Segmentation
FIG. 3 : Global NK Market, by Treatment, 2018 (US$ Mn)
FIG. 4 : Global NK Market, by Geography, 2018 (US$ Mn)
FIG. 5 : Attractive Investment Proposition: by Geography, 2018
FIG. 6 : Competitive Analysis: Global NK Market, by Key Players, 2018
FIG. 7 : Global Preservative Free Artificial Tears Market for NK, 2017 – 2027 (US$ Mn)
FIG. 8 : Global Topical Antibiotics Market for NK, 2017 – 2027 (US$ Mn)
FIG. 9 : Global Tarsorraphy Market for NK, 2017 – 2027 (US$ Mn)
FIG. 10 : Global Amniotic Membrane Transplantation Market for NK, 2017– 2027 (US$ Mn)
FIG. 11 : Global Bandage Contact Lenses Market for NK, 2017 – 2027 (US$ Mn)
FIG. 12 : Global Recombinant Human Nerve Growth Factor Market for NK, 2017 – 2027 (US$ Mn)
FIG. 13 : U.S. NK Market, 2017 – 2027 (US$ Mn)
FIG. 14 : Canada NK Market, 2017 – 2027 (US$ Mn)
FIG. 15 : U.K. NK Market, 2017 – 2027 (US$ Mn)
FIG. 16 : Germany NK Market, 2017 – 2027 (US$ Mn)
FIG. 17 : Rest of Europe NK Market, 2017 – 2027 (US$ Mn)
FIG. 18 : China NK Market, 2017– 2027 (US$ Mn)
FIG. 19 : Japan NK Market, 2017 – 2027 (US$ Mn)
FIG. 20 : Rest of Asia Pacific NK Market, 2017 – 2027 (US$ Mn)
FIG. 21 : Brazil NK Market, 2017 – 2027 (US$ Mn)
FIG. 22 : Mexico NK Market, 2017 – 2027 (US$ Mn)
FIG. 23 : Rest of Latin America NK Market, 2017 – 2027 (US$ Mn)
FIG. 24 : GCC NK Market, 2017 – 2027 (US$ Mn)
FIG. 25 : Rest of Middle East and Africa NK Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 : Global Neurotrophic Keratitis (NK) Market Portraiture
TABLE 2 : Global NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 3 : Global NK Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 4 : North America NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 5 : North America NK Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 6 : Europe NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 7 : Europe NK Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 8 : Asia Pacific NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 9 : Asia Pacific NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 : Latin America NK Market, by Treatment, 2017 – 2027 (US$ Mn)
TABLE 11 : Latin America NK Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 : Middle East and Africa NK Market, by Treatment, 2017– 2027 (US$ Mn)
TABLE 13 : Middle East and Africa NK Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 : Allergan, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 : Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 : Bausch & Lomb Incorporated: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 : Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 : CooperVision: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 : Dompe farmaceutici S.p.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 : Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 : Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 : ReGenTree, LLC.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 : Walgreens: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Question:

What is the size of Neurotrophic Keratitis Market?

The market for Neurotrophic Keratitis Market is expected to reach USD$ XX in 2027.

What is the Neurotrophic Keratitis Market CAGR?

The Neurotrophic Keratitis Market is expected to see significant CAGR growth over the coming years, at 5.2%.

What is the Forecast period considered for Neurotrophic Keratitis Market?

The report is forecasted from 2019 -2027.

What is the base year considered for Neurotrophic Keratitis Market?

The base year of this report is 2018.

Who are the major players in this market?

keratitis are Allergan, Plc., Abbott Laboratories, Inc., Bausch & Lomb Incorporated, Bayer AG. are some of the major players in the global market.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –